Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
2026 and planned Phase 3 and Phase 2b trial initiations for nalbuphine ER in idiopathic pulmonary fibrosis and refractory chronic cough patients, respectively. This progress highlights Trevi's effort to position nalbuphine ER across multiple chronic cough indications, potentially broadening its future addressable treatment landscape. We'll now examine how Trevi's planned transition of nalbuphine ER into Phase 3 trials could influence the company's broader investment narrative. AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. For Trevi, the crux of the investment story is whether nalbuphine ER can become a meaningful chronic cough franchise before the cash and dilution pressures bite too hard. The newly announced End-of-Phase 2 FDA meeting and planned Phase 3 IPF chronic cough and Phase 2b RCC trials tighten the near t
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.MarketBeat
- Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare ConferencePR Newswire
- MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 1/12/26 - Form 4
- 1/12/26 - Form 3
- 12/5/25 - Form 8-K
- TRVI's page on the SEC website